Finally, An Apoptosis-Targeting Therapeutic for Cancer.
Finally, An Apoptosis-Targeting Therapeutic for Cancer.
复制标题
DOI：
10.1158/0008-5472.can-16-1248
复制
发表时间：
2016-10-15
期刊：
影响因子：
11.2
通讯作者：
Reed JC
中科院分区：
文献类型：
--
作者：
Croce CM;Reed JC
对细胞死亡的抵抗是癌症的标志之一。恶性细胞中的各种遗传和表观遗传变化在面对基因组不稳定性、癌基因活化、微环境应激、化疗、靶向抗癌药物甚至免疫治疗时提供细胞保护。细胞生命和死亡调节因子的核心是Bcl-2家族蛋白，该家族的创始成员（B细胞淋巴瘤/白血病-2）是通过参与淋巴瘤中的染色体易位而发现的。寻找靶向细胞生存蛋白Bcl-2的治疗方法代表了一条漫长的道路，有许多死胡同，失望和延误。最后，一种靶向Bcl-2的药物已被批准作为一类新的抗癌药物。
Resistance to cell death represents one of the hallmarks of cancer. Various genetic and epigenetic changes in malignant cells afford cytoprotection in the face of genomic instability, oncogene activation, microenvironment stress, chemotherapy, targeted anticancer drugs and even immunotherapy. Central among the regulators of cell life and death are Bcl-2 family proteins, with the founding member of the family (B-cell lymphoma/leukemia-2) discovered via its involvement in chromosomal translocations in lymphomas. The quest for therapeutics that target cell survival protein Bcl-2 represents a long road traveled, with many dead-ends, disappointments, and delays. Finally, a Bcl-2-targeting medicine has gained approval as a new class of anticancer agent.